# Precipio, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Precipio, Inc.).

## Overview

Precipio, Inc. is a U.S.-based healthcare biotechnology company focused on cancer diagnostics. It develops and commercializes diagnostic products and pathology services through its clinical laboratory operations and product division.

## Products & services

• Cancer diagnostic products
• Pathology services
• Clinical laboratory testing
• Diagnostic product development and validation
• Distributor-supported laboratory sales

- **Pathology services** (89%) — Clinical laboratory testing and diagnostic pathology services performed through the New Haven CLIA lab.
- **Diagnostic products** (11%) — Cancer-focused laboratory products sold directly and through distributors.

- Cancer diagnostic products
- Pathology services
- Clinical laboratory testing
- Diagnostic product development and validation
- Distributor-supported laboratory sales

## Customers

Precipio sells to laboratories, pathology practices, and healthcare organizations that need cancer diagnostic testing or related products. Its product business also reaches labs through national distributors, while its clinical lab services are used by patients and referring providers seeking pathology analysis.

- **Clinical laboratories** (primary) — Buy diagnostic products and consumables for use in laboratory workflows and testing
- **Pathology practices and providers** (primary) — Use pathology services for cancer-related diagnostic interpretation and testing
- **Healthcare distributors** (secondary) — Purchase and distribute products to reach laboratory customers nationwide
- **Patients and referring physicians** (secondary) — Receive pathology services through the company’s clinical laboratory operations

- Clinical laboratories buying diagnostic products for routine use
- Pathology practices using lab services for cancer diagnostics
- Healthcare distributors reselling products into lab channels
- Patients and referring physicians served through pathology testing

## Geography

Precipio is based in the United States and operates primarily through its New Haven, Connecticut clinical laboratory. The company states that it mainly serves the U.S. market, while its products may also be sold in other countries through global healthcare distributors.

- Headquartered and operating in the United States
- New Haven CLIA laboratory is a core operating site
- Primary commercial focus is the U.S. laboratory market
- Products may be sold internationally through distributors

## Strategy

Precipio’s strategy is built around using its own clinical laboratory as a development and validation engine for new diagnostic products. It also relies on distributor partnerships to broaden access to laboratories and accelerate commercialization of its cancer diagnostics portfolio.

- **Use the clinical lab as a product development platform** (short-term) — Internal testing and validation reduce development time and improve product fit for real workflows
- **Expand distributor-led product commercialization** (medium-term) — National distributors extend reach into laboratory customers without building a large direct sales footprint
- **Build cancer diagnostics offerings that address misdiagnosis** (long-term) — The company’s product pipeline is centered on solving diagnostic accuracy problems in oncology

- Use the CLIA lab to develop and validate products faster
- Leverage in-house use of products to improve credibility
- Expand reach through major healthcare distributors
- Accelerate commercialization of cancer diagnostic solutions

## Risks

Precipio faces execution risk from dependence on reimbursement, billing operations, and access to capital, which are important for a company combining services and product development. It is also exposed to regulatory, trade, and tariff changes, as well as clinical and product-development risks typical of diagnostics businesses.

- **Billing and reimbursement disruption** [high] — Pathology services depend on third-party billing systems and payer remittances, so interruptions can delay cash collection
- **Liquidity and financing dependence** [critical] — The business needs external funding and revenue growth to support operations and obligations
- **Regulatory and reimbursement risk** [high] — Clinical laboratory and diagnostic businesses are sensitive to healthcare regulation and payer policy
- **Trade and tariff exposure** [medium] — Imported goods or supplier inputs may become more expensive under tariff changes
- **Product development and validation risk** [medium] — New diagnostics require specimens, skilled staff, and successful validation before commercialization

- Billing and reimbursement disruptions can delay cash collection
- Regulatory changes can affect lab operations and product sales
- Trade tariffs may raise input costs or disrupt supply chains
- Product development depends on access to specimens and skilled staff
- Going-concern risk reflects ongoing funding needs

## Accounting

Precipio’s results are affected by revenue recognition judgments in both pathology services and product sales, including reimbursement adjustments and allowances for credit losses. Investors should also watch estimates tied to going-concern disclosures, receivables, and any liabilities or recoveries related to billing disruptions and government credits.

- **Revenue recognition and reimbursement adjustments** — Affects quarterly service revenue and receivables
- **Allowance for credit losses** — Affects reported net sales
- **Going concern and liquidity assumptions** — Affects financial statement presentation and risk disclosure
- **Billing-related liabilities and recoveries** — Affects other liabilities and cash flow

- Service revenue depends on reimbursement estimates and adjustments
- Product revenue is recognized separately from pathology services
- Allowance for credit loss affects reported service revenue
- Going-concern disclosures reflect funding and liquidity assumptions
- Receivables and billing-related liabilities can move results materially

---

*Last updated: 2026-04-29T04:49:19.019325+00:00*